madman
Super Moderator
New Data from Marius Pharmaceuticals Reveals High Prevalence of Low Libido, Energy and Quality of Life in Men
RALEIGH, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for...
RALEIGH, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, has released compelling new insights from a recent Androgen Deficiency in Aging Males (qADAM) questionnaire conducted on their KYZATREX® (testosterone undecanoate) CIII capsules website. The data collected from 779 participants highlights significant challenges faced by men regarding energy, libido, strength and overall life satisfaction, underscoring the potential impact of testosterone deficiency on quality of life and well-being.
Below are the results from men who responded to the qADAM questionnaire, a validated tool for assessing testosterone deficiency symptoms:
- 75% rated their libido as poor or terrible
- 76% rated their energy level as poor or terrible
- 66% rated their strength and/or endurance as poor or terrible
- 62% rated their enjoyment of life as poor or terrible
- 46% rated their happiness level as poor or terrible
- 72% rated the strength of their erections as somewhat or extremely weak
- 53% rated their work performance over the past 4 weeks as poor or terrible
- 59% fall asleep at least 3-4x/week after eating dinner
- 72% rated their sports ability over the past 4 weeks as poor or terrible
Together, this data reflects a broader pattern of symptoms often associated with low testosterone, highlighting the need for accessible solutions to support men experiencing these challenges. View the infographic for a detailed results breakdown.
"This data reinforces the necessity for greater awareness and resources to address men's health concerns, particularly testosterone deficiency, which can profoundly affect physical and emotional well-being," said Amit Shah, Chief Operating Officer of Marius Pharmaceuticals. "At Marius, we are committed to providing safe, effective options for managing low testosterone with products like KYZATREX."
KYZATREX is an FDA-approved oral form of testosterone replacement therapy (TRT) indicated for adult males experiencing low or no testosterone due to certain medical conditions. A six-month clinical trial demonstrated that KYZATREX was up to 96% effective at Day 90 at restoring normal testosterone levels in adult men who have low or no testosterone levels due to certain medical conditions.1,2*
*Per label, 88% of patients had low testosterone levels at Day 90 (worst-case scenario calculation, excluding Site 104). Based on patients who completed the study (n=127), 96% of patients achieved normal testosterone levels at Day 90.1
Testosterone deficiency, also known as hypogonadism, affects millions of men worldwide and is associated with various chronic conditions, including obesity, diabetes and depression.3,4 As the global demand for men’s health solutions grows, Marius Pharmaceuticals continues to prioritize patient-centered therapies, empowering men to take control of their health and well-being.
For more information on KYZATREX, visit www.kyzatrex.com.
